PSORIATIC ARTHRITIS (PSA)

This study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored f…

This early-stage study tests a new drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The goal is to check safety and how the drug affects the body. Participants receive multiple doses and are monitored for side effect…

This study tests whether a TNF inhibitor (adalimumab biosimilar) is better than methotrexate at preventing bone damage in people with early psoriatic arthritis. About 108 adults with active disease and symptoms for less than 2 years will be randomly assigned to one of the two dru…

This study looks at whether people with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who are doing well on a JAK inhibitor can safely reduce their dose. About 200 participants will either lower their dose or stay on the same dose, guided by disease activi…

This study tests whether a dermatologist's physical exam is better than a patient questionnaire at spotting psoriatic arthritis (PsA) in people with psoriasis. About 500 adults with psoriasis will be checked by both methods, then referred to a rheumatologist for a final diagnosis…

This study is testing a new blood-based test that aims to predict which medication will work best for each person with rheumatic diseases like rheumatoid arthritis or lupus. Researchers will take a blood sample and analyze immune cells to create a personalized treatment profile. …

This study tests whether using a carotid ultrasound (a neck scan) to find hidden plaque in arteries can help prevent heart attacks and strokes in people with inflammatory rheumatic diseases like rheumatoid arthritis or lupus. About 1,944 participants aged 50 and older will be spl…

This early-stage study tests an experimental drug called LPX-TI641 in 48 adults with rheumatoid arthritis or psoriatic arthritis. Participants take the drug or a placebo daily for 28 days. The main goal is to check if the drug is safe and tolerable, and how it moves through the b…

This study looks at how weight loss (using tirzepatide) and a biologic drug (ixekizumab) affect the body in people with psoriatic arthritis who are overweight or obese. About 45 adults will receive one or both treatments. Researchers will take samples of skin, joint tissue, and f…

This study follows 425 adults with recent psoriatic arthritis (PsA) for up to 10 years to see how many develop joint damage and what factors predict it. Researchers will use X-rays and other data to identify early signs of aggressive disease. The goal is to help doctors decide wh…

This study looks at 200 adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis to see if certain blood markers (related to oxidative stress) can help doctors monitor how the disease changes over a year. Participants give blood samples at the start, 6 mon…

This research study collects health information from 10,000 people with brain inflammation conditions like Long COVID, ME/CFS, and autoimmune diseases. Participants use a smartphone app to share symptoms, health history, and wearable data. The goal is to find disease subtypes and…

This study will follow 700 adults with axial spondyloarthritis or psoriatic arthritis who have recently started one of several newer treatments (bimekizumab, upadacitinib, risankizumab, guselkumab, or a TNF inhibitor). Researchers will collect medical records and patient surveys …